James W. Janc

1.5k citations

51 papers · 1.1k indexed · h-index 22

Co-authors: Kyle Elrod P.P.A. Humphrey Craig A. Townsend Bret M. Benton Mathai Mammen Paul A. Sprengeler Christopher S. Lunde B.A. Katz
Topics: Blood Coagulation and Thrombosis Mechanisms (10 papers)Coagulation, Bradykinin, Polyphosphates, and Angioedema (9 papers)Protease and Inhibitor Mechanisms (8 papers)
Cited by: Hematology Molecular Medicine Organic Chemistry
Journals: Journal of the American Chemical Society Journal of Biological ChemistrySHILAP Revista de lepidopterología
Partner nations: United States Switzerland Australia

In The Last Decade

James W. Janc

50 papers receiving 1.1k citations

Peers

Countries citing papers authored by James W. Janc

Since Specialization

Citations

This map shows the geographic impact of James W. Janc's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James W. Janc with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James W. Janc more than expected).

Fields of papers citing papers by James W. Janc

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James W. Janc. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James W. Janc. The network helps show where James W. Janc may publish in the future.

Co-authorship network of co-authors of James W. Janc

This figure shows the co-authorship network connecting the top 25 collaborators of James W. Janc. A scholar is included among the top collaborators of James W. Janc based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James W. Janc. James W. Janc is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Synthesis and characterization of soquelitinib a selective ITK inhibitor that modulates tumor immunity 2024 ·(unknown),James T. Rosenbaum,Erik Verner,William B. Jones,Craig Hill,James W. Janc,Joseph J. Buggy,Rahul D. Pawar,Poorva Ghosh,(unknown),(unknown),John Reneau,Michael S. Khodadoust,Youn H. Kim,Ryan A. Wilcox,Richard A. Miller	3
2	Efficacy of telavancin, a lipoglycopeptide antibiotic, in experimental models of Gram-positive infection 2014 ·Expert Review of Anti-infective Therapy ·Sharath S. Hegde,James W. Janc	7
3	Impact of telavancin on prothrombin time and activated partial thromboplastin time as determined using point-of-care coagulometers 2013 ·Journal of Thrombosis and Thrombolysis ·(unknown),(unknown),Jack L. Harbert,James W. Janc,(unknown),Steven L. Barriere	6
4	Effects of telavancin on coagulation test results 2011 ·International Journal of Clinical Practice ·Steven L. Barriere,Michael R. Goldberg,James W. Janc,Deborah L. Higgins,(unknown),Dorothy Adcock	13
5	Factor VIIa inhibitors: Gaining selectivity within the trypsin family 2006 ·Bioorganic & Medicinal Chemistry Letters ·William D. Shrader,Aleksandr Kolesnikov,(unknown),Roopa Rai,(unknown),Huiyong Hu,(unknown),(unknown),Wendy B. Young,B.A. Katz,Christine Yu,Jie Tang,(unknown),(unknown),James W. Janc,Paul A. Sprengeler	12
6	Factor VIIa inhibitors: Chemical optimization, preclinical pharmacokinetics, pharmacodynamics, and efficacy in an arterial baboon thrombosis model 2006 ·Bioorganic & Medicinal Chemistry Letters ·Wendy B. Young,Joyce Mordenti,(unknown),William D. Shrader,Aleksandr Kolesnikov,Roopa Rai,Liang Liu,Huiyong Hu,Ellen M. Leahy,Michael J. Green,Paul A. Sprengeler,B.A. Katz,Christine Yu,James W. Janc,Kyle Elrod,Ulla M. Marzec,Stephen R. Hanson	24
7	Design of novel, potent, and selective human β-tryptase inhibitors based on α-keto-[1,2,4]-oxadiazoles 2006 ·Bioorganic & Medicinal Chemistry Letters ·Chang-Sun Lee,Weili Liu,Paul A. Sprengeler,John R. Somoza,James W. Janc,David Sperandio,Jeffrey R. Spencer,Michael J. Green,Mary E. McGrath	11
8	Discovery of novel hydroxy pyrazole based factor IXa inhibitor 2006 ·Bioorganic & Medicinal Chemistry Letters ·(unknown),Paul A. Sprengeler,Michael B. Shaghafi,Jeffrey R. Spencer,(unknown),Christine Yu,Roopa Rai,Wendy B. Young,Brian E. Schultz,James W. Janc	12
9	Factor VIIa inhibitors: Improved pharmacokinetic parameters 2006 ·Bioorganic & Medicinal Chemistry Letters ·Aleksandr Kolesnikov,Roopa Rai,Wendy B. Young,Joyce Mordenti,Liang Liu,(unknown),William D. Shrader,Ellen M. Leahy,Huiyong Hu,(unknown),James W. Janc,B.A. Katz,Paul A. Sprengeler	9
10	Generation of potent coagulation protease inhibitors utilizing zinc-mediated chelation 2005 ·Bioorganic & Medicinal Chemistry Letters ·Wendy B. Young,Paul A. Sprengeler,William D. Shrader,Yong Li,Roopa Rai,Erik Verner,Thomas E. Jenkins,(unknown),Aleksandr Kolesnikov,James W. Janc,Lynne Cregar,Kyle Elrod,(unknown)	9
11	3,4-Disubstituted azetidinones as selective inhibitors of the cysteine protease cathepsin K. Exploring P3 elements for potency and selectivity 2005 ·Bioorganic & Medicinal Chemistry Letters ·Eduardo L. Setti,Dana Davis,James W. Janc,Douglas A. Jeffery,(unknown),(unknown)	25
12	Dissecting and Designing Inhibitor Selectivity Determinants at the S1 Site Using an Artificial Ala190 Protease (Ala190 uPA) 2004 ·Journal of Molecular Biology ·B.A. Katz,Christine Luong,Joseph D. Ho,John R. Somoza,(unknown),Jie Tang,Steven R. Williams,Erik Verner,Richard L. Mackman,Wendy B. Young,Paul A. Sprengeler,(unknown),Kyle Mortara,James W. Janc,Mary E. McGrath	29
13	Practical Robust Fit of Enzyme Inhibition Data 2004 ·Methods in enzymology on CD-ROM/Methods in enzymology ·Petr Kuzmič,Craig Hill,James W. Janc	13
14	Kinetic determination of tight-binding impurities in enzyme inhibitors 2003 ·Analytical Biochemistry ·Petr Kuzmič,Craig Hill,(unknown),James W. Janc	4
15	Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-directed Serine Protease Inhibitors 2003 ·Journal of Molecular Biology ·B.A. Katz,Kyle Elrod,Erik Verner,Richard L. Mackman,Christine Luong,William D. Shrader,Martin Sendzik,Jeffrey R. Spencer,Paul A. Sprengeler,(unknown),Vincent W.‐F. Tai,Hon C. Hui,J. Guy Breitenbucher,Darin A. Allen,James W. Janc	30
16	Highly potent non-peptidic inhibitors of the HCV NS3/NS4A serine protease 2002 ·Bioorganic & Medicinal Chemistry Letters ·David Sperandio,Anthony R. Gangloff,Joane Litvak,Richard Goldsmith,Jason Hataye,(unknown),Emma Shelton,Kyle Elrod,James W. Janc,James M. Clark,Kenneth Rice,(unknown),Kap‐Sun Yeung,Nicholas A. Meanwell,Dennis Hernandez,(unknown),Brian L. Venables,Jeffrey R. Spencer	29
17	Engineering inhibitors highly selective for the S1 sites of Ser190 trypsin-like serine protease drug targets 2001 ·Chemistry & Biology ·B.A. Katz,Paul A. Sprengeler,Christine Luong,Erik Verner,Kyle Elrod,(unknown),James W. Janc,Jeffrey R. Spencer,J. Guy Breitenbucher,Hon C. Hui,D. P. C. MCGEE,Darin A. Allen,(unknown),Richard L. Mackman	51
18	Structure–activity relationship studies of a bisbenzimidazole-based, Zn2+-dependent inhibitor of HCV NS3 serine protease 2001 ·Bioorganic & Medicinal Chemistry Letters ·(unknown),Nicholas A. Meanwell,Zhilei Qiu,Dennis Hernandez,Sharon Zhang,Fiona McPhee,(unknown),James M. Clark,James W. Janc	34
19	A novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site11Edited by D. Rees 2001 ·Journal of Molecular Biology ·B.A. Katz,Kyle Elrod,Christine Luong,Mark J. Rice,Richard L. Mackman,Paul A. Sprengeler,Jeffrey R. Spencer,Jason Hataye,James W. Janc,John O. Link,Joane Litvak,Roopa Rai,Kenneth Rice,Steve Sideris,Erik Verner,Wendy B. Young	61
20	A kinetic investigation of phosphoenolpyruvate carboxylase from Zea mays 1992 ·Biochemistry ·James W. Janc,Marion H. O’Leary,W. W. Cleland	36

About James W. Janc

James W. Janc is a scholar working on Genetics, Hematology and Immunology and Allergy, having authored 51 papers that have together received 1.1k indexed citations. Recurring topics across this work include Blood Coagulation and Thrombosis Mechanisms (10 papers), Coagulation, Bradykinin, Polyphosphates, and Angioedema (9 papers) and Protease and Inhibitor Mechanisms (8 papers). The work is most often cited by research in Hematology (120 citations), Molecular Medicine (51 citations) and Organic Chemistry (287 citations). James W. Janc has collaborated with scholars based in United States, Switzerland and Australia. Frequent co-authors include Kyle Elrod, P.P.A. Humphrey, Craig A. Townsend, Bret M. Benton, Mathai Mammen, Paul A. Sprengeler, Christopher S. Lunde, B.A. Katz, Petr Kuzmič and Steve Sideris. Their work appears in journals such as Journal of the American Chemical Society, Journal of Biological Chemistry and SHILAP Revista de lepidopterología.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact